메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Suguru Odajima (Department of Obstetrics and Gynecology The Jikei University School of Medicine Tokyo Japan) Toshiyuki Seki (Department of Obstetrics and Gynecology The Jikei University School of Medicine Tokyo Japan) Sayako Kato (Department of Obstetrics and Gynecology Daisan Hospital The Jikei University School of Medicine Tok) Keisuke Tomita (Department of Obstetrics and Gynecology Kashiwa Hospital The Jikei University School of Medicine Ch) Yuichi Shoburu (Department of Obstetrics and Gynecology The Jikei University School of Medicine Tokyo Japan) Eitaro Suzuki (Department of Obstetrics and Gynecology Katsushika Medical Center The Jikei University School of Me) Masataka Takenaka (Department of Obstetrics and Gynecology The Jikei University School of Medicine Tokyo Japan) Motoaki Saito (Department of Obstetrics and Gynecology Kashiwa Hospital The Jikei University School of Medicine Ch) Hirokuni Takano (The Jikei University Kashiwa Hospital Kashiwa Japan) Kyosuke Yamada (Department of Obstetrics and Gynecology Daisan Hospital The Jikei University School of Medicine Tok) Aikou Okamoto (The Jikei University School of Medicine)
저널정보
대한부인종양학회 Journal of Gynecologic Oncology Journal of Gynecologic Oncology Vol.33 No.5
발행연도
2022.9
수록면
1 - 13 (13page)
DOI
https://doi.org/10.3802/jgo.2022.33.e62

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Objective: Direct oral anticoagulants (DOACs) are increasingly being used for the treatment of cancer-associated venous thromboembolism (CAT). However, there is limited evidence of the efficacy of DOACs for the treatment of gynecological CAT. Thus, this study aimed to investigate the efficacy and safety of edoxaban for the treatment of gynecological CAT using Japanese real-world data. Methods: We reviewed the medical records of patients with 371 gynecological cancer who received edoxaban or vitamin K antagonist (VKA) between January 2011 and December 2018. Results: Altogether, 211 and 160 patients were treated with edoxaban and VKA, respectively. Fourteen patients (6.8%) in the edoxaban group and 22 (13.8%) in the VKA group showed recurrence of venous thromboembolism (VTE). Cumulative VTE recurrence was not significantly different between the 2 groups (p=0.340). Adverse events occurred in 15 (7.1%) and 11 (6.9%) patients in the edoxaban and VKA groups, respectively (p=0.697). Subgroup analysis of the edoxaban and VKA groups according to different tumor types, including ovarian, endometrial, and cervical cancer, showed equivalent outcomes in terms of VTE recurrence and adverse events. Patients without pulmonary embolism (PE) were mostly omitted from initial unfractionated heparin (UFH) therapy prior to administration of edoxaban. However, this did not increase the recurrence of VTE. Conclusion: This study confirmed that edoxaban is effective and safe for the treatment of gynecological CAT. This finding was consistent for different types of gynecological cancer. Additionally, initial UFH therapy prior to the administration of edoxaban may be unnecessary for patients without PE.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0